Healthcare
Elanco Animal Health Incorporated(ELAN)
Live Price
Offline$24.22
+3.55% today
1Y Change
+76.02%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $11.49B
- Revenue Growth
- +6.2%
- EPS Growth
- -169.1%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Elanco Animal Health Incorporated (ELAN) is a Healthcare stock with a market cap of $11.49B and listed on NYSE. The stock last traded around $24.22 and up 76.0% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +6.2%, EPS growth of -169.1%, a dividend yield of 0.0%. What stands out right now is revenue +6.2%, EPS -169.1%, free cash flow -27.9% with operating margin 9.0% and ROIC 3.7%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ELAN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.2% vs +7.6% peer median
Operating Margin
Below sector median
+9.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +6.2% and EPS is at -169.1%, with operating margin around 9.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -8.3% | -16.7% | -5.6% |
2026 Feb 24, 2026 | +18.2% | +1.7% | -5.7% | -5.6% |
2025 Nov 5, 2025 | +46.1% | -0.4% | +2.1% | +1.8% |
Benchmark Edge
ELAN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELAN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELAN Max Drawdown
-26.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ELAN and SPY.
Company Overview
Elanco Animal Health Incorporated
New York Stock Exchange
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
- Leadership
- Jeffrey N. Simmons
- IPO Date
- Sep 20, 2018
- Employees
- 9.0k
- Street Address
- 2500 Innovation Way
- Mailing
- Greenfield, IN, 46140
- Region
- Greenfield, IN, US
- Reporting Currency
- USD
- Investor Line
- 877 352 6261
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 19.8
- Price/Sales
- 2.3
- Price/Book
- 1.7
Growth
- Revenue
- +6.2%
- EPS
- -169.1%
- Free Cash Flow
- -27.9%
Profitability
- Gross Margin
- 49.4%
- Operating Margin
- 9.0%
- Net Margin
- -4.9%
- ROE
- -3.7%
- ROIC
- 3.7%
Balance Sheet
- Debt/Equity
- 0.61
- Current Ratio
- 2.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.